Alexandria Real Estate Equities: A Paradox of Strong Fundamentals and Quarterly Loss

Alexandria Real Estate Equities, a leading real estate investment trust specializing in life science properties, has released its financial results for the fourth quarter and full year 2025. The figures present a complex picture: a robust balance sheet stands in stark contrast to a significant quarterly net loss, while management signals caution through a modest dividend adjustment.

Financial Results: Losses and Operational Metrics

For the three-month period ending December 2025, Alexandria reported a net loss of $1.08 billion, equating to $6.35 per share. This contributed to a full-year 2025 loss per share of $8.44. A more favorable measure of ongoing business performance, the Adjusted Funds From Operations (Adjusted FFO), came in at $2.16 per share for the quarter. Total quarterly revenue reached $754.41 million.

Operational activity remained robust despite the bottom-line loss. The company leased 1.2 million square feet of space during Q4, which included 393,376 square feet of previously vacant space. Portfolio occupancy stood at 90.9% as of December 31. However, the report noted downward pressure on rental rates, with renewals experiencing a 9.9% decline in cash rents and new leases seeing a 5.2% decrease.

Liquidity, Debt Management, and Capital Allocation

The company’s financial position is characterized by significant strength and prudence. Alexandria ended 2025 with substantial liquidity of $5.30 billion. It recently repaid $300 million of maturing senior unsecured notes. The debt structure is notably stable, with 97.2% of outstanding borrowings at fixed rates and maturities spread over the long term; only 11% of total liabilities are due before 2028.

Should investors sell immediately? Or is it worth buying Alexandria Real Estate Equities?

In a move reflecting confidence in its intrinsic value, the board has authorized a new share repurchase program for up to $500 million, effective through the end of 2026. The quarterly dividend on common stock was declared at $0.72 per share, representing a slight reduction from previous levels.

2026 Guidance and Sector Outlook

Management reaffirmed its full-year 2026 outlook, projecting Adjusted FFO to range between $6.25 and $6.55 per share.

The broader life science real estate sector is anticipated to stabilize in 2026. Key drivers for this expected equilibrium include a slowdown in new construction, a resurgence in venture capital funding, and a gradual rebalancing of supply and demand within major innovation clusters. Long-term fundamentals are supported by sustained scientific innovation, a strategic shift toward domestic manufacturing, and demographic-driven demand for new therapies. The imminent completion of new laboratory facilities could contribute to a more balanced market environment as early as this year.